Examine the comparative availability of DPP-4 Inhibitor versus Alfa-glycosidase inhibitor for the type 2 diabetic patient who was treated with Pioglitazone or Metohormine

Examine the comparative availability of DPP-4 Inhibitor versus Alfa-glycosidase inhibitor for the type 2 diabetic patient who was treated with Pioglitazone or Metohormine - Study for an ultimate combination therapy to control diabetes with Sitagliptin-1

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004675

Enrollment

114

Registered

2010-12-07

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Pioglitazone or Metohormine + Stagliptin Pioglitazone or Metohormine + Alfa-glycosidase inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with type 2 diabetes 2)Patients with suboptimal glycemic control by Pioglitazone or Metohormine for more than 2 months treatments. 3)Age >=20 years, <80 years (Male and Female) 4)A consent form for participating in this study is submitted

Exclusion criteria

Exclusion criteria: 1)Patients with type 1 diabetes 2)History of severe ketosis, diabetic coma or precoma within 6 months 3)Patients with severe infections, before or after operation, or with serious trauma 4)Patients with exceeding the moderate renal impairment 5)Patients with history of stroke, MI or other sever vascular complication which required a hospitalization within six months. 6)Patients receiving DPP-4 Inhibitor except Sitagliptin 7)Patients receiving Alfa-glycosidase inhibitor, Sulfonylurea or Glinide during obtaining the informed consent or received Insulin treatment in the past 2 months. 8)Patients who are pregnant, breastfeeding or intention to becoming pregnant 9)Having allergy to DPP-4 Inhibitor or Alfa-glycosidase inhibitor 10)Other patients determined to be inappropriate by physician

Design outcomes

Primary

Measure	Time frame
Change of HbA1c from the baseline to 12 weeks later	—

Countries

Japan

Contacts

Public ContactKazuki Kobayashi

Graduate School of Medicine, Chiba University Clinical Cell Biology and Medicine

koba-chi@faculty.chiba-u.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026